Apr 27, 2026
Intellia Reports Positive Pivotal Trial Results for CRISPR-Based Treatment of Rare Swelling Disease
Intellia Therapeutics announced that its CRISPR-based gene editing treatment reduced swelling attacks in a pivotal trial for hereditary angioedema, a rare genetic disease. The results advance the CRISPR field's one-and-done treatment approach toward potential regulatory approval.
1 source
00